Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS

Key Points

• Renaissance Technologies increased its Krystal Biotech stake by 190.9% in the first quarter, ending with 9,600 shares valued at approximately $2.48 million. Institutional investors collectively own 86.29% of KRYS.
• Krystal Biotech reported quarterly EPS of $1.79, exceeding the $1.70 analyst consensus, while revenue of $119.22 million fell slightly short of expectations.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $361.56, compared with the reported share price of $326.45.

Renaissance Technologies LLC lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 190.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,600 shares of the company's stock after purchasing an additional 6,300 shares during the quarter. Renaissance Technologies LLC's holdings in Krystal Biotech were worth $2,480,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Sound Income Strategies LLC lifted its position in Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company's stock worth $34,000 after purchasing an additional 127 shares during the period. Greenline Wealth Management LLC bought a new stake in Krystal Biotech in the fourth quarter valued at about $34,000. Danske Bank A S acquired a new position in Krystal Biotech in the third quarter worth about $35,000. UMB Bank n.a. lifted its stake in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after purchasing an additional 37 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock valued at $39,000 after purchasing an additional 142 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $326.45 on Monday. The firm has a market cap of $9.66 billion, a price-to-earnings ratio of 40.91 and a beta of 0.53. Krystal Biotech, Inc. has a 12 month low of $133.00 and a 12 month high of $382.54. The stock has a 50-day moving average price of $341.38 and a 200 day moving average price of $297.69.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. Sell-side analysts predict that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares of the company's stock, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company's stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,642 shares of company stock worth $8,243,923 over the last 90 days. 13.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on KRYS shares. Jefferies Financial Group restated a "buy" rating and set a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. Chardan Capital raised Krystal Biotech to a "strong-buy" rating in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 3rd. Evercore reaffirmed an "outperform" rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Finally, Bank of America increased their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a "buy" rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $361.56.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source